Home
About Us
Partnered Assets
Latest News
Team
Careers
Contact Us
No menu assigned!
Developing novel immunotherapies for autoimmune disease and cancer
ImmuNext's anti-CD40L antagonist enters THIRD Sanofi-led Phase 2 trial
NCT05039840
Learn about our other immunotherapy assets.
Home
About Us
Partnered Assets
Latest News
Team
Careers
Contact Us